Please use this identifier to cite or link to this item: https://doi.org/10.3390/biomedicines9121776
DC FieldValue
dc.titleExploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease
dc.contributor.authorBhave, Sayali
dc.contributor.authorHo, Han Kiat
dc.date.accessioned2022-06-17T05:37:58Z
dc.date.available2022-06-17T05:37:58Z
dc.date.issued2021-12-01
dc.identifier.citationBhave, Sayali, Ho, Han Kiat (2021-12-01). Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. BIOMEDICINES 9 (12). ScholarBank@NUS Repository. https://doi.org/10.3390/biomedicines9121776
dc.identifier.issn2227-9059
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/227177
dc.description.abstractRecently, non-alcoholic fatty liver disease (NAFLD) has emerged as a predominant health concern affecting approximately a quarter of the world’s population. NAFLD is a spectrum of liver ailments arising from nascent lipid accumulation and leading to inflammation, fibrosis or even carcinogenesis. Despite its prevalence and severity, no targeted pharmacological intervention is approved to date. Thus, it is imperative to identify suitable drug targets critical to the development and progression of NAFLD. In this quest, a ray of hope is nestled within a group of proteins, receptor tyrosine kinases (RTKs), as targets to contain or even reverse NAFLD. RTKs control numerous vital biological processes and their selective expression and activity in specific diseases have rendered them useful as drug targets. In this review, we discuss the recent advancements in characterizing the role of RTKs in NAFLD progression and qualify their suitability as pharmacological targets. Available data suggests inhibition of Epidermal Growth Factor Receptor, AXL, Fibroblast Growth Factor Receptor 4 and Vascular Endothelial Growth Factor Receptor, and activation of cellular mesenchymal-epithelial transition factor and Fibroblast Growth Factor Receptor 1 could pave the way for novel NAFLD therapeutics. Thus, it is important to characterize these RTKs for target validation and proof-of-concept through clinical trials.
dc.language.isoen
dc.publisherMDPI
dc.sourceElements
dc.subjectnon-alcoholic fatty liver diseases
dc.subjectreceptor tyrosine kinases
dc.subjectsteatosis
dc.subjectfibrosis
dc.subjectEGFR
dc.subjectc-MET
dc.subjectAXL
dc.subjectFGFR
dc.subjectVEGFR
dc.typeArticle
dc.date.updated2022-06-17T05:32:34Z
dc.contributor.departmentDEPT OF PHARMACY
dc.contributor.departmentOFFICE OF STUDENT AFFAIRS
dc.description.doi10.3390/biomedicines9121776
dc.description.sourcetitleBIOMEDICINES
dc.description.volume9
dc.description.issue12
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. .pdf713.24 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.